热景生物公告称，公司于11月11日召开董事会，审议通过以集中竞价交易方式回购股份方案。回购资金 1亿-2亿元，来源为自有资金，价格不超244元/股，拟回购409,837-819,672股，占总股本0.44%-0.88%， 用于员工持股计划或股权激励。回购期限自董事会审议通过起12个月内。此外，控股股东等相关人员在 决议前6个月内有减持，回购期间暂无明确增减持计划。本次回购存在价格、资金、重大事项等风险。 ...

格隆汇11月11日丨热景生物(688068.SH)公布，截至本公告日，控股股东、实际控制人、董事长兼总经 理林长青通过集中竞价、大宗交易方式累计减持公司股份100万股，占公司总股本的1.0787%。本次减 持计划已实施完毕。 ...

格隆汇11月11日丨热景生物(688068.SH)公布，截至2025年11月10日，本次股份回购计划实施完毕，公 司已实际通过回购公司股份869.70万股，占公司总股本的3.19%，回购的最高成交价格为13.19元/股，最 低成交价格为10.77元/股，使用资金总额为1.00亿元（不含交易佣金等交易费用）。 ...

格隆汇11月11日丨热景生物(688068.SH)公布，截至本公告日，控股股东、实际控制人、董事长兼总经 理林长青通过集中竞价、大宗交易方式累计减持公司股份100万股，占公司总股本的1.0787%。本次减 持计划已实施完毕。 ...

每经AI快讯，11月11日，热景生物(688068.SH)公告称，公司拟以自有资金通过集中竞价交易方式回购 部分公司股票，回购资金总额不低于10,000万元(含)，不超过20,000万元(含)，用于员工持股计划或股权 激励。回购价格不超过244元/股(含)，回购期限自董事会审议通过之日起12个月内。 ...

Market Overview - The medical device sector experienced a slight decline of 0.13% on November 11, with Danaher Biomedical leading the drop [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Top Performers - Anxu Bio (688075) saw a closing price of 42.54, with an increase of 4.39% and a trading volume of 23,700 [1] - Nanwei Medical (688029) closed at 86.17, up 3.89% with a trading volume of 31,700 [1] - Yirui Technology (688301) closed at 109.90, increasing by 2.65% with a trading volume of 22,000 [1] Underperformers - Danaher Biomedical (920009) closed at 77.69, down 4.91% with a trading volume of 16,300 [2] - Ruimait (301367) closed at 86.41, down 4.32% with a trading volume of 18,600 [2] - Tianchen Medical (688013) closed at 52.68, down 3.59% with a trading volume of 26,900 [2] Capital Flow - The medical device sector saw a net outflow of 642 million yuan from institutional investors, while retail investors contributed a net inflow of 463 million yuan [2][3] - The top net inflows from retail investors were observed in Nanwei Medical (688029) with 46.22 million yuan, and Tianchen Medical (688013) with 24.78 million yuan [3]

Core Viewpoint - The A-share market has seen a significant rise in flu-related stocks due to a noticeable increase in flu activity across China, with most provinces entering the flu epidemic period [1] Group 1: Stock Performance - Hendi Pharmaceutical has increased by over 14%, while Hualan Biological has risen by 11% [1] - Other notable performers include Peking University Pharmaceutical with a 10% increase, and Jinshi Yao with a rise of over 7% [1] - Several companies, including Teva Pharmaceutical, Erkang Pharmaceutical, and others, have also shown gains of over 5% [1] Group 2: Market Context - Recent data from the China CDC indicates that flu virus cases have surpassed other respiratory viruses, marking a significant shift in the current flu season [1] - Since mid-October, sales of related medications, such as Oseltamivir, have increased, with production running continuously [1]

证券代码：688068 证券简称：热景生物 公告编号：2025-074 北京热景生物技术股份有限公司 （一） 股东会召开的时间：2025 年 11 月 10 日 （二） 股东会召开的地点：北京市大兴区中关村科技园区大兴生物医药产业基 地庆丰西路 55 号公司三层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 225 | | --- | --- | | 普通股股东人数 | 225 | | 2、出席会议的股东所持有的表决权数量 | 54,762,407 | | 普通股股东所持有表决权数量 | 54,762,407 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 62.8608 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 62.8608 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和 ...

北京德恒律师事务所 关于北京热景生物技术股份有限公司 2025 年第四次临时股东会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于北京热景生物技术股份有限公司 2025 年第四次临时股东会的法律意见 北京德恒律师事务所 关于北京热景生物技术股份有限公司 2025年第四次临时股东会的 德恒 01G20250768 号 致：北京热景生物技术股份有限公司 北京德恒律师事务所（以下简称"本所"）受北京热景生物技术股份有限公 司（以下简称"公司"）委托，本所指派律师（以下简称"本所承办律师"）出席 了公司2025年第四次临时股东会（以下简称"本次股东会"），对公司本次股东会 的召集与召开程序、出席会议人员的资格与召集人的资格、会议表决程序与表决 结果等有关事项出具见证意见。 本法律意见根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市 公司股东会规则》（以下简称"《股东会规则》"）等有关法律、法规和规范性文件， 以及《北京热景生物技术股份有限公司章程》（以下简称"《公司章程》"） ...

Core Viewpoint - The stock of Beijing Hotgen Biotech Co., Ltd. increased by 5.32% on November 10, reaching a price of 143.50 yuan per share, with a trading volume of 276 million yuan and a turnover rate of 2.11%, resulting in a total market capitalization of 13.304 billion yuan [1]. Company Overview - Beijing Hotgen Biotech Co., Ltd. was established on June 23, 2005, and went public on September 30, 2019. The company is located in the Daxing District of Beijing and specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments [1]. - The revenue composition of the company includes: 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from other sources, and 1.17% from biological raw materials [1]. Fund Holdings - According to data, one fund under Huaxia Fund has a significant holding in Hotgen Biotech. The Huaxia SSE STAR 200 ETF (588820) increased its holdings by 28,000 shares in the third quarter, bringing the total to 29,600 shares, which accounts for 1.06% of the fund's net value, making it the tenth largest holding [2]. - The Huaxia SSE STAR 200 ETF (588820) was established on December 23, 2024, with a latest scale of 476 million yuan. Year-to-date, it has achieved a return of 53.55%, ranking 500 out of 4217 in its category, and a cumulative return of 52.86% since inception [2]. Fund Manager Information - The fund manager of the Huaxia SSE STAR 200 ETF (588820) is Hualong. As of the report date, Hualong has been in the position for 3 years and 82 days, managing total assets of 35.957 billion yuan. The best fund return during this period was 107.73%, while the worst was -15.08% [3].